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ABSTRACT 
Background: Notification of hepatitis C (HCV) positive status is known to have 
short-term impacts on subsequent alcohol, drug use and injection behaviors among 
persons who inject drugs (PWID). Whether post-screening behavioral changes extend 
over time for PWIDs, and whether screening test notification has behavioral impacts 
among HCV-negative PWIDs, remain to be established. This study sought to 
longitudinally assess substance use and injection behaviors after HCV status notification 
among HCV seroconverters and HCV-negative PWIDs.  
Methods: Initially HCV-seronegative PWIDs (n=208) were followed 
prospectively between 2004 and 2011 in Montreal, Canada. Semi-annual screening visits 
included blood sampling and an interview-administered questionnaire assessing 
substance use and injection behaviors. Multivariable general estimating equations (GEE) 
analyses were conducted to assess substance use and behavior changes over time, and 
compare changes between HCV seroconverters and HCV-seronegative subjects while 
adjusting for baseline characteristics. 
Results: Of the 208 participants (83% male; mean age 34.7 years, mean follow-up 
time 39 months), 69 (33.2%) seroconverted to HCV. A linear decrease in syringe sharing 
behavior was observed over time after HCV+ and HCV- status notification, whereas a 
10% decrease for each additional 3-month follow-up was observed for injection cocaine 
and heroin use among HCV seroconverters, but not among HCV-seronegative PWIDs 
(p<0.05). No significant changes were observed in alcohol use.  
Conclusions: Our results indicate that notification of HCV-positive status is 
associated with reduced injection drug use among seroconverters.  Amongst PWIDs 
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deemed seronegative after screening, there is no sustained trend for change in risk 
behavior.    
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Illicit injection drug use is the most important cause of new hepatitis C infection 
worldwide [1].  In Canada, 83% of the estimated 8,000 yearly new HCV infections occur 
among persons who inject drugs (PWID) [2].  It is largely acknowledged that an 
integrated harm-reduction strategy involving early access and broad coverage to a 
combination of interventions is required to control HCV transmission [3, 4]. These 
approaches and assumptions are largely based on data generated through HIV research, 
and endorsed by the World Health Organization, the United Nations AIDS and the United 
Nations Office on Drugs and Crime [5]. Specific evidence of their effectiveness for HCV 
prevention is, however, considered weak [6].  It has also been suggested that HCV testing 
programs that combine screening and counseling can decrease HCV transmission by 
reducing risk behaviors among uninfected PWIDs as well as chronically HCV-infected 
injectors [4].  Yet, HCV screening programs were found only moderately cost effective, 
although an associated decrease in needle-sharing by 5% annually substantially improved 
their cost-effectiveness [7].  
Hence, it is unclear whether HCV status awareness, after testing, and counseling 
can influence behaviors and reduce risk of transmission. Moreover, whether any behavior 
change extends over time remains to be established. Most studies on HCV screening and 
awareness relied on cross-sectional study designs, and yielded diverse results.  Lower 
alcohol use [8] and injection risk behaviors [9, 10] were observed among PWIDs aware 
of their HCV positive status in some studies, but not in others [11, 12].  Only three 
studies have prospectively examined changes in behaviors after HCV status notification 
among PWIDs.  In Baltimore, reductions in syringe sharing at 3 to 6 months after HCV 
notification were observed for less than a fifth of participants, all HCV-positive at 
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recruitment [13]. In Melbourne, Australia, an increased use of new syringes was observed 
after HCV peer-delivered testing and counseling among both HCV-positive and negative 
PWIDs [14]. Finally, in a cohort of young PWIDs in San Francisco, recent HCV 
infection post-screening notification and counseling was followed by an initial decrease 
in alcohol and non-injection drug use, but no statistically significant change in injection 
drug use, and these changes were not sustained at 6 and 12-month follow-up [15]. None 
of these three studies has specifically compared the effect of HCV status notification 
between HCV-positive and HCV-negative PWIDs.  
This study, conducted in a population of HCV-seronegative active injection drug 
users recruited and followed longitudinally between 2004 and 2011 in Montreal, Canada, 
aimed to i) longitudinally assess substance use and injection behaviors following HCV 
status notification, and ii) to compare changes overtime between PWIDs who received a 
positive result and those who stayed negative. Hence, this study has the potential to 
provide valuable information on the effect of counseling given the serostatus notification. 
Methods 
Population: 
The study population was drawn from the St. Luc Cohort, an open cohort of 
PWIDs established in Montreal in 1988 to study determinants of HIV transmission.  In 
late 2004 the study focus was expanded to include determinants of HCV, and HEPCO, an 
embedded cohort of HCV-negative PWIDs, was constituted. To be eligible for 
recruitment into HEPCO, participants are required to be current PWIDs (i.e., as having 
injected drugs within the previous six months), negative for HCV antibodies, and be 18 
years of age or older.  
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A detailed description of the recruitment and follow-up procedures has been 
previously published [16]. HEPCO includes HCV and HIV-negative participants already 
followed in the St. Luc cohort (30%), as well as new participants recruited through street-
level strategies such as word-of-mouth (36%) or through community program referrals 
(34%). Participants who stopped injection for more than 24 months are no longer 
followed. All participants signed an informed consent in compliance with institutional 
review board regulations of the Centre Hospitalier de l’Université de Montréal (CHUM). 
Cohort visits were scheduled at six-month intervals and consisted of behavioral 
questionnaires administered by trained interviewers as well as venous blood samples 
drawn for HIV and HCV antibody testing.  Participants were asked to return for their 
serostatus test results two weeks after their visits, at which time post-test counseling and 
referrals were provided. Syringes and condoms were provided upon request, and 
Hepatitis B immunization was offered through the CHUM clinic next door. All 
participants received a CAD $15.00 stipend at each visit. Seroconverting participants 
were systematically referred for medical follow-up and treatment assessment to the 
CHUM Addiction Medicine program, which offers multidisciplinary services for patients 
with drug-related problems, including hepatitis C treatment.   
For the total number of individuals included in HEPCO (n= 345), 208 participants 
(60%) who had undergone at least three visits between November 2004 and March 2011 
were included in this investigation. All seroconverters had a documented negative HCV 
antibody test at the time of enrolment, a subsequent positive HCV antibody test during a 
follow-up visit, and at least one other follow-up visit.  We found no differences in 
baseline characteristics between the 208 participants who completed at least three visits 
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and, thus, were included in the main analyses, and the remaining 137 cohort members 
(data not shown). 
Measures: 
Several outcome variables were examined to assess potential changes associated 
with notification of HCV status. Drug use and injection behavior outcomes were chosen 
because of their positive association with HCV acquisition previously observed in our 
population [16]. Measures included cocaine, heroin and illicit prescription opioid (mainly 
hydromorphone, hydrocodone and fentanyl) injection, as well as syringe sharing defined 
as the use of a syringe already used by someone else.  In addition, alcohol use was chosen 
for its clinical relevance in relation to liver disease. All outcomes were measured by 
questions pertaining to use within the past 6 months, expressed as dichotomous variables 
(yes/no).  
HCV infection was detected by the presence of HCV antibodies. A positive HCV 
antibody test was determined by enzyme immunoassay assay (EIA - Abbott Laboratories) 
and confirmed by reverse transcription polymerase chain reaction (RT-PCR-Roche 
Diagnostic Systems).  Indeterminate results were sent for confirmation by dual EIA 
and/or recombinant immunoblot assay. 
To deal with the potential decrease in risk behaviors over time among cohort 
participants exposed to serial counseling [17, 18], we redefined the ‘baseline’ visit, at 
which the characteristics of the participants were compared in this investigation.  For 
seroconverters, the visit immediately preceding the seroconversion visit was selected as 
the ‘baseline’.  For each PWID who remained seronegative, consecutive numbers were 
first assigned to each follow-up visit since recruitment. One of these numbers was then 
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randomly selected to represent ‘baseline’.  As shown in Figure 1, that selection for 
baseline visits enabled the resulting distribution to be frequency-matched between the 
seroconverter and the seronegative groups. 
Statistical analyses:  
Descriptive statistics used to summarize the participants’ baseline characteristics 
included means, standard deviations (SD), medians and interquartile ranges (IQR) for 
continuous variables, and frequency distributions for categorical variables. To compare 
the baseline characteristics according to HCV serostatus, we used the chi-square test  for 
categorical variables.  For continuous variables, we used the independent groups t-test for 
normally distributed variables or the non-parametric Wilcoxon test if the normality 
assumption was violated. 
Main analyses were performed separately for each outcome.  Analyses focused on 
changes over time in the frequency of the corresponding binary outcome across all post-
baseline visits (‘baseline’ as described in the ‘Measures’ section above). A multivariable 
generalized estimating equations (GEE) extension of logistic regression, with 
autoregressive order 1 covariance structure, was used to account for the correlation of 
consecutive outcome measures for the same subject [19]. First, separate GEE models 
were estimated for the HCV-seroconverters and HCV-seronegative subjects. These 
subgroup-specific models estimated the effect of a continuous variable indicating time-
since-baseline, while adjusting for age and gender, as well as for the baseline value of the 
binary indicator of the behavior being assessed.  The effect of time was estimated through 
the adjusted odds ratio (OR), with 95% confidence interval (CI), and its statistical 
significance was assessed with a model-based Wald test at a 2-tailed α=0.05. Next, to 
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compare changes over time between HCV-seroconverter and HCV-seronegative subjects, 
a multivariable GEE model was estimated using data on all participants. This model 
included, in addition to the time variable, (i) baseline covariates and the baseline value of 
the behavior being assessed, (ii) a binary indicator of the seroconversion group, and (iii) a 
two-way interaction between the time and the seroconversion group indicator. The test of 
the interaction was then used to assess if the rates of change in the respective behavior 
did differ significantly between the two groups.  
Preliminary analyses assessed whether the changes in specific behaviors over time 
were consistent with the linearity assumption. We first employed the flexible Generalized 
Additive Model (GAM) extension of logistic regression, with spline smoothing [20, 21] 
to estimate potentially non-linear changes in each behavior and each group. If the visually 
inspection of the GAM plots suggested possible non-linearity of changes, the 
corresponding GEE model was expanded to include interactions with quadratic and cubic 
functions of time.  Because, for all outcomes, the non-linear interactions were definitely 
non-significant (all p-values > 0.15), the final analyses were limited to linear changes 
over time.  
Significance level of 0.05 was used for all statistical tests. All statistical analyses 




The majority of participants were male (83.1%), with a mean and median age of 
34.1 (SD 9.6) and 31.8 (IQR: 26.6-41.2) years. The mean and median duration of 
injection-drug use was 10.0 (SD 8.6) and 8.2 (IQR: 3.6-13.2) years. Of the 208 
participants analyzed, 69 individuals (33.2%) seroconverted to HCV, an incidence rate 
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(IR) of 14.4 per 100 person-years (95% confidence interval (CI): 11.3, 18.1).  Participants 
contributed a total of 528 person-years of observation to this investigation. The mean and 
median follow-up time was 30.4 (SD 17.3) and 27.9 (IQR: 15.7-45.1) months.  The 
median time between consecutive visits was 5.9 months. At the end of 2011, rates of 
attrition and discontinuation of follow-up (> 24 months without injection) were 10.1% 
and 4.3% among HCV seroconverters and 13.6% and 11.5% among HCV negative 
participants respectively.  
Table 1 compares the baseline characteristics of the 208 participants according to 
their HCV status. Compared to participants who remained HCV-negative, those who 
seroconverted to HCV were significantly more likely to report injecting cocaine (87.0% 
vs. 63.3%), opioids (50.7% vs. 22.3%), and to report sharing of syringes (39.1% vs. 
23.7). 
Table 2 presents the results of analyses of changes in drug use behaviors, 
estimated through the GEE models. The two columns report the adjusted odds ratios 
(OR’s), for each additional 3 months of follow-up, separately for subjects who have been 
informed about their HCV positive or negative serostatus. Figure 2 displays the 
proportion of participants reporting each outcome at 6-month interval, for participants 
who seroconverted and those who stayed seronegative separately. For most behaviors, 
there is no evidence of systematic changes overtime in the HCV seronegative group, 
graphically and as estimated by OR’s close to 1.0 and the 95% CI’s that include 1.0. In 
contrast, for HCV seroconverters, all analyses indicated a decrease in the frequency of 
the corresponding behavior, and most of these decreases were statistically significant. For 
example, among participants who seroconverted to HCV, the odds of subsequent 
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injections of cocaine (OR=0.90, 95% CI: 0.85-0.94) or heroin (OR= 0.90, 0.83-0.97) 
decreased by 10% with each additional 3 months of follow-up. The pattern of these 
changes in the HCV seroconverters was consistent with the linearity assumption, which 
suggests the trend to gradual reduction of these behaviors applied across the follow-up 
period.  No such changes were observed among PWIDs who stayed seronegative.  
Consistent with these results, statistically significant (p<0.05) interactions (last column of 
Table 2) indicate that participants who were informed that they had contracted HCV were 
more likely to report having stopped cocaine and heroin injections. Both groups reported 
statistically significant decreases over time in the odds of sharing syringes, and these 
changes were greatest among those who seroconverted to HCV. Finally, the changes in 
alcohol use were smaller than for other behaviors and did not vary according to HCV 
seroconversion status. 
Discussion 
Our results indicate that HCV-seronegative PWIDs living in Montreal are 
polydrug users at high-risk of HCV infection.  Altogether, close to a third of participants 
in our study reported having shared a syringe in the past 6 months.  Not surprisingly, 
PWIDs who seroconverted were more likely to report syringe sharing, compared to 
participants who remained seronegative. They were also more likely to report opioid 
injection, a factor independently associated with seroconversion in our setting [16]. The 
main finding of this study is that notification of HCV test results and counseling is related 
to reductions in subsequent drug use behavior for PWIDs learning that they recently 
contracted an HCV infection, but not for those who are uninfected. This is the first time, 
to our knowledge, that changes in risk behaviors after HCV notification have been shown 
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to vary according to serostatus. As time-since-notification increased, seroconverters 
underwent a linear decrease in cocaine and heroin injection whereas no such decrease 
was observed among PWIDs who remained seronegative. Short-term behavioral changes 
following individual awareness of HCV screening status have been reported among 
HCV-positive individuals [9, 10]. Evidence that changes persist over time has not 
previously been ascertained.  For example, in a cohort of young injectors aged between 
15 and 24 years old, post-screening changes in drug use behavior were less consistent and 
were not sustained [8]. Age differences might be implicated, the mean age for our cohort 
being 34 years old. Young PWIDs have been shown not to be concerned by an HCV 
infection diagnosis when they go through intense periods of drug consumption and street 
involvement [22].  
Reductions in drug use behaviors are likely to reflect a response to being 
informed about the recent seroconversion. The notion of “teachable moment” has been 
used in the disease prevention literature, to describe health events thought to motivate 
individuals to spontaneously adopt risk-reduction health behaviors [23]. Notification of 
abnormal test results has been shown to prompt lifestyle changes among patients with a 
variety of conditions, including cancer, HIV, and cardiovascular diseases [24-26]. For 
PWIDs who became seropositive in this study, the notification of a newly acquired 
diagnosis may be a cue prompting motivation for change to improve their own health or 
to reduce the risk of infecting others.  In a study examining patient’s priorities relative to 
HCV counseling in a clinical setting, the combined risk of viral transmission to family 
members and others represented the principal volunteered concern among newly 
diagnosed and follow-up patients alike [27]. It is also possible that changes in behaviors 
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are partially explained by increased intervention. In our study, participants recently 
infected were offered, in addition to counseling and support, a personalized reference to a 
multidisciplinary team for assessment and the possibility of being treated. Unfortunately, 
we did not have information on treatment uptake among our participants.  Regular 
follow-up in a multidisciplinary setting and the perspective of getting cured might have 
triggered persistent changes in some of the participants [28]. 
Aside from a differential impact of the notification and of consequent 
interventions, the difference in the magnitude of changes observed between the two 
groups could be attributed to the possibility that PWIDs staying HCV-seronegative had 
modified their behavior prior to enrolment in this study. It was recently demonstrated that 
many long-term PWIDs engage in planning strategies to avoid risk behaviors [29]. In 
addition, as shown in Figure 2, a higher proportion of participants stopped being followed 
because they have stopped injecting for more than 2 years compared to the seroconverter 
group. 
Typically, alcohol use is not a predominant item in prevention messages for 
PWIDs. The observation that changes in alcohol use was relatively modest in both groups 
should raise concerns, given the recent recommendations by the United States Center for 
Disease Control in August 2012. One of the reasons invoked for this public health 
measure, aside from HCV detection and treatment, was to increase awareness on alcohol-
related harm for those already infected with the virus [30]. At least for PWIDs, this does 
not seem to translate in significant changes over time. Pairing alcohol abuse interventions 
with HCV screening may be needed to truly have an impact on alcohol use behaviors. 
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Our study presents strength and limitations.  The sample population provides a 
unique opportunity to study the impact of HCV status notification among active injectors 
likely to have engaged in recent risky behaviors and potentially amenable to change. 
Participants were not randomly selected, and our study excluded HIV-infected 
individuals, hence our sample cannot be considered an adequate representation of the 
Montreal PWID population as a whole. Even though follow-up was fairly high for a 
drug-using population, and that no difference was found between participants retained 
and those lost at inception, our data may have been influenced by losses to follow-up. 
Long-term changes should be interpreted with caution given the smaller number of 
subjects followed in later years of follow-up. Although there is some published evidence 
to suggest that drug users do provide reliable and valid responses, the risk of bias if it 
exists, is more likely to go unreported [31]. In addition, we did not have information on 
HCV treatment uptake after HCV notification, and mental health status, variables that 
could have influenced behavior changes.   
Altogether, our results suggest that it is mainly the notification of the HCV 
positive status that induces the decrease in risk among PWIDs while there is no sustained 
trend for change in risk among those who continue to be seronegative.  A new research 
agenda should aim at identifying what « works », e.g. whether it is the impact of the 
result itself (new infection), the impact of intensified counseling, and support the 
reference for care, or a combination of all these actions. Also, specific and possibly 
sustained intervention should be developed, studied and eventually implemented for 
those screened negative for HCV. The identification of health events, meaningful for 
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PWIDs at the time of HCV status notification, whether testing positive or negative, could 
enhance the impact of counseling and willingness to initiate changes. 
In the meantime, our study underscore the need for regular and individualized 
HCV screening and counseling for all PWIDs with linkage to HCV treatment and opiate 
substitution therapy when appropriate.  
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Table 1: Participant characteristics at study baseline, according to serostatus 
communicated at the disclosure visit. 
Variable  All participants     
n=208 (%) 
HCV seroconverters         
n=69 (%) 
HCV negative           
n=139 (%) 
p-value 
Male gender  173 (83.1) 60 (87.0) 113 (81.2) 0.294 
Less than 30 years of 
age  
72 (34.6) 29  (42.0) 43 (30.9) 0.113 
College education or 
higher  
31 (14.9) 8  (11.6) 23 (16.6) 0.345 
Total income ≥ $6000 
CDN  
103 (49.3) 36 (52.2) 67 (47.8) 0.555 
Alcohol use past 6 
months  
151 (72.6) 45 (65.2) 106 (76.3) 0.092 
IV heroin use  past 6 
months 
84 (40.4) 33 (47.8) 51 (36.7) 0.123 
IV opioid use  past 6 
months 
66 (31.7) 35 (50.7) 31 (22.3) <0.0001 
IV cocaine use  past 6 
months 
148 (71.2) 60 (87.0) 88 (63.3) 0.0004 
Crack use  past 6 
months 
111 (53.4) 40 (58.0) 71 (51.1) 0.348 
Cannabis use  past 6 
months 
146 (70.2) 51 (73.9) 95 (68.4) 0.408 
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Sharing syringes  past 
6 months 
60 (28.9) 27 (39.1) 33 (23.7) 0.021 
 26 
Table 2:   Changes of drug use behaviors overtime , by 3-month increment, stratified 
according to post-screening disclosure of HCV status. 
** if p<0.01; * if 0.01<p≤0.05 
a 
Adjusted for baseline value of each of the outcome of interest, age and gender, 
respectively 
b
 2-sided p-value for the test of the interaction between the time and the group indicator, 
in the GEE model; p<0.05 indicates that the rate of changes in a given behavior over time 
Behaviors of 
interest 
HCV seroconverters         
N = 69 
HCV negative            
N = 139 
 
 Adjusted Odds Ratio 
a
 and 95% confidence 
interval  





Alcohol use past 6 
months 
0.94 (0.89, 1.00)* 0.97 (0.92, 1.03) 0.441 
Cocaine injection  
past 6 months 
0.90 (0.85, 0.94)** 0.97 (0.93, 1.02) 0.019 
Heroin injection 
past 6 months 
0.90 (0.83, 0.97)** 1.00 (0.94, 1.06) 0.046 
Opioid injection 
past 6 months 
0.93 (0.87, 1.00)* 1.00 (0.94, 1.07) 0.132 
Sharing syringes 
past 6 months 
0.85 (0.77, 0.94)**
 
0.92 (0.85, 0.99)* 0.220 
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differs significantly between the two groups
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Figure 1  
Title: 
Distribution of visits selected to serve as baseline for participants who seroconverted to 
HCV and participants who stayed HCV-seronegative. 
 
Legend: 
The baseline visits used for this study were frequency matched by the number of visits 




Proportion of participants reporting each outcome at 6-month intervals, stratified by the 
serostatus notification.   
 
 
 
